Why Did Peptide Science Close Down?

Peptide Science News

Peptide Sciences, one of the most recognizable names in the research peptide market, voluntarily shut down operations in early March 2026 — a closure driven not by a single event but by the most aggressive regulatory crackdown the grey-market peptide industry has ever faced. The company’s homepage now displays only a brief farewell message, marking the end of an era for thousands of researchers and biohackers who relied on the Henderson, Nevada-based vendor for years. This peptide science news sent shockwaves through the community: if a supplier this established could disappear overnight, no grey-market vendor is safe. The closure is not an isolated incident. At least seven research peptide companies shut down in 2025 alone, and the forces that felled Peptide Sciences — FDA enforcement, DOJ criminal prosecutions, Big Pharma legal action, and the collapse of the GLP-1 compounding loophole — continue to intensify across the entire industry.

The Official Statement and What It Reveals

Peptide Sciences’ website at peptidesciences.com now shows a single message: “After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products. We are deeply grateful for your trust and support. Thank you for being part of the Peptide Sciences community.” No further explanation was provided. No forwarding address, no timeline for refunds, no mention of what happens to customer data.

The word “voluntarily” is the most revealing detail in this brief statement. It signals a calculated business decision rather than a forced shutdown — the company chose to close its doors before regulators kicked them in. Dr. Steven Murphy, writing on his Substack on March 6, 2026, called the closure “something quietly seismic” and observed that Peptide Sciences “existed in the strange legal twilight that has defined the peptide market for years. Their peptides were labeled clearly: ‘for research use only.’ Not for human consumption. Not intended as medicine. But anyone paying attention understood the reality.” Murphy’s analysis frames the shutdown as evidence that “the old model — anonymous research vendors supplying molecules that ultimately end up in human experimentation — may be becoming harder to sustain.”

The closure’s timing coincides with an unprecedented convergence of regulatory forces. Daniel Brzezinski, the company’s founder identified through Crunchbase, has not issued any public statement. The company’s last substantive social media activity on X/Twitter was a November 2024 post about Cagrilintide research — months of silence preceding the final shutdown.

A Decade of Dominance, Then a 2023 FDA Warning Letter

Peptide Sciences operated for roughly a decade as one of the most prominent US-based research peptide suppliers. The micro-business — just 2–10 employees generating under $5 million in annual revenue — punched well above its weight in market visibility. Its catalog featured approximately 120 peptides spanning the most sought-after compounds in the biohacking community: BPC-157, TB-500, semaglutide, tirzepatide, retatrutide, CJC-1295, ipamorelin, sermorelin, Melanotan II, GHK-Cu, and many more. The company also offered popular blends like BPC-157/TB-500 combinations and a “Glow Blend” combining BPC-157, TB-500, and GHK-Cu.

The company claimed 99%+ purity on all products, citing partnerships with WHO/GMP and ISO 9001:2015 approved sources, with all peptides manufactured in the USA via lyophilization. Certificates of Analysis were provided using HPLC and mass spectrometry. However, a critical weakness lurked beneath these claims: testing was internal, not independently verified. A 2026 MagellanRx analysis noted that “no publicly available evidence shows consistent third-party lab testing. The COAs provided function as internal quality documentation rather than independent verification.” This distinction would prove significant as quality concerns mounted.

Reviews were mixed but trended positive overall. Trustpilot showed a 3.2 out of 5 rating across roughly 59 reviews, while WorthEPenny aggregated 141 reviews at 4.0 out of 5. Long-time customers praised the quality — one Eroids reviewer wrote, “I have been using peptide sciences for at least 7 years… They have all been top notch and they arrive in a couple of days.” Critics complained about strict no-return policies, slow customer service, and pricing that ran higher than competitors. One Sitejabber reviewer reported that “Peptide Science sold me bunk Gonadorelin. It had no effect, so I had it lab-tested, and it came back highly diluted.” More troublingly, independent testing flagged by Tom Howard on X/Twitter found that “Retatrutide from Peptide Sciences recently does not contain Retatrutide,” and Outliyr reported seeing third-party tests showing purity as low as 75% on some products.

The pivotal moment came in 2023, when Peptide Sciences received an FDA warning letter for making health claims about research peptides. According to ThePeptideList on Medium, “the company marketed BPC-157 and TB-500 with references to ‘healing’ and ‘recovery,’ crossing the line from research chemical sales to drug marketing.” Peptide Sciences restructured its website and marketing to comply. But the warning letter put the company firmly on the FDA’s radar — and the regulatory environment was about to get dramatically worse.

The Regulatory Tsunami That Made the Business Model Untenable

The forces that ultimately drove Peptide Sciences’ closure began building in September 2023, when the FDA placed 17 popular peptides on its Category 2 Bulk Drug Substance list, effectively banning compounding pharmacies from producing BPC-157, TB-500, AOD-9604, CJC-1295, ipamorelin, Epitalon, GHK-Cu, MOTS-c, and others. The FDA cited “risk for immunogenicity, peptide-related impurities, and limited safety-related information.” This single action didn’t directly target “research use only” vendors like Peptide Sciences, but it signaled a fundamental shift in the agency’s posture toward the entire peptide ecosystem.

What followed was an escalating enforcement campaign without precedent in the peptide industry. According to PeptideExaminer’s complete 2024–2026 enforcement timeline, in December 2024, the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs. That same month, the Pharmacy Compounding Advisory Committee voted against allowing compounding of ipamorelin, MK-677, CJC-1295, and AOD-9604. In February 2025, the FDA declared the semaglutide shortage resolved, eliminating the legal basis under which hundreds of compounding pharmacies had been producing GLP-1 agonists — a massive revenue stream for the broader peptide industry.

The enforcement escalation turned physical in June 2025, when FDA agents raided Amino Asylum’s warehouse, forcing one of the largest grey-market research chemical vendors offline overnight. By September 2025, the FDA had issued more than 50 warning letters to GLP-1 compounders with confirmed DOJ involvement, and 30 telehealth companies received warnings for misleading advertising of compounded GLP-1 drugs. State attorneys general joined the fight — Alabama obtained a temporary restraining order against GLP-1 distributors, Connecticut settled with “Triggered Brand” for selling raw semaglutide powder with self-injection instructions, and 40+ state attorneys general formally petitioned the FDA about counterfeit peptides entering the US market.

Perhaps most chilling for vendors like Peptide Sciences was the criminal prosecution of Tailor Made Compounding LLC, which pleaded guilty to distributing unapproved drugs including BPC-157 and faced a $1.79 million forfeiture. Separately, All American Peptide’s owners pleaded guilty to conspiracy charges involving $3+ million in forfeitures. These cases established clear precedent: selling peptides for human use, regardless of disclaimers, could result in prison time and financial ruin.

Jay Campbell of BioLongevity Labs summarized the situation bluntly in a message to industry affiliates: “The federal government — DOJ, FBI, and FDA — has decided that RUO peptide manufacturing and distribution can no longer sell, manufacture, or distribute injectable peptides or bioregulators. Anything injectable is now toast.“

What the Community Is Saying About the Closure

Because the shutdown occurred on or very near March 6, 2026, community reaction is still in its earliest stages. The first analytical coverage came from Dr. Steven Murphy’s Substack, published the same day. One commenter, Aggie Hewitt, MD, MSc, predicted: “I’m sure this will occur with Pura Peptides, Simple Peptides and many others.” A Facebook post from The Dolce Diet declared: “BREAKING NEWS!!! The peptide industry is collapsing!”

Among industry insiders, the dominant sentiment is resignation — this was viewed as an inevitable consequence of regulatory tightening. In the longevity and biohacking community, the mood leans toward frustration with government overreach and worry about losing trusted supply sources. Some physicians view it as an opportunity for the industry to move toward properly regulated medicine.

Notably, this does not appear to be a scam or exit scam. Peptide Sciences operated for many years with an established presence, the shutdown message is professional, and the closure aligns with an industry-wide pattern of vendors shutting down under regulatory pressure. ScamAdviser had rated the site as “likely legit” with a positive trust score. However, real concerns exist about pending orders and refunds — Peptide Sciences maintained a strict no-return, no-refund policy even before closing, and it remains unclear whether the company’s support email is still monitored. Customers who stored payment information on the site may also have legitimate data privacy concerns, though the domain was registered through a privacy protection service.

Prior to the full shutdown, Peptide Sciences had already taken the intermediate step of removing all GLP-1 peptides (semaglutide, tirzepatide, retatrutide) from its catalog. PeptideCritic documented this, noting that “PeptideSciences is not a random Telegram reseller. It has historically been one of the more mainstream, visible, compliance-minded vendors in this space.” The GLP-1 removal was evidently not enough — within months, the entire operation was shuttered.

Seven Peptide Companies Shut Down in 2025, and the List Keeps Growing

Peptide Sciences is far from alone. The broader peptide science news story is one of systemic industry contraction. Confirmed closures and enforcement actions in 2025 alone include Amino Asylum (FDA warehouse raid, June 2025), Peptide Tech, Research Chem, Royal Research, American Research, and Unchained Compounds — all shuttered. Eli Lilly filed an International Trade Commission complaint (Investigation No. 337-TA-1386) targeting multiple vendors selling imported tirzepatide, naming Strate Labs, Arctic Peptides, Swiss Chems, Paradigm Peptides, GenX Peptides, and others. A General Exclusion Order now prohibits all importation of products containing or purporting to contain tirzepatide that infringe Lilly’s trademark.

The FDA has also begun using AI to scrape vendor websites for hidden dosing information that contradicts “research use only” disclaimers — a technological escalation that makes the traditional grey-market model even riskier. As the legal firm Frier Levitt noted, “FDA has stated such disclaimers were a ruse to avoid FDA scrutiny for selling misbranded and adulterated products.”

The market data underscores how explosive growth invited regulatory attention. Chinese peptide imports to the US doubled to $328 million in 2025, and online peptide advertising surged 678% since 2022. FDA testing found that up to 40% of online and compounded peptides contained incorrect dosages or undeclared ingredients. Two women were hospitalized and placed on ventilators after peptide injections at a longevity conference in Las Vegas in 2025. These safety incidents gave regulators powerful ammunition.

An intriguing political wildcard complicates the outlook. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience that approximately 14 of 19 restricted Category 2 peptides will be moved back to Category 1, making them legal for compounding again. Kennedy called the original FDA ban “illegal” and acknowledged it “created the gray market.” However, legal experts at LumaLex Law cautioned: “Political commentary and regulatory action are not the same. No FDA rule has changed. No Federal Register notice has been issued.” Even if the reversal materializes, it would benefit compounding pharmacies rather than grey-market “research use only” vendors — potentially further marginalizing the business model Peptide Sciences represented.

Three Alternatives for Researchers Seeking Peptide Suppliers

With Peptide Sciences gone, researchers and biohackers need reliable alternatives. Three suppliers stand out based on current community reputation, testing standards, and operational track record.

1. PekCura Labs

PekCura Labs (pekcuralabs.com), based in Florida, has emerged as a quality-focused option with arguably the strongest testing transparency in the industry. The company offers approximately 32 peptides in two tiers — GMP-grade and research-grade — including BPC-157 (GMP 10mg at $79.99, research-grade at $59.99), TB-500, ipamorelin, MOTS-C, Selank, and Tesamorelin, along with GLP-1 compounds sold under coded names. PekCura’s defining feature is its dual third-party testing through an ISO 17025:2017-accredited laboratory, with every batch undergoing HPLC purity analysis, LAL endotoxin testing, sterility testing, and heavy metals screening. QR codes on every vial link directly to batch-specific COAs — a level of traceability that exceeded what Peptide Sciences offered. Trustpilot reviews sit at 4.3 out of 5 from 27 reviews with 81% five-star ratings. One reviewer wrote: “ANYONE who spends the money for a 3rd party testing site speaks VOLUMES to me.” The company ships from Florida with free delivery on orders over $100 and typical two-business-day delivery. The main caveats are its relatively small track record, occasional stock availability issues, and reports that payment methods may be limited to Venmo.

2. Biotech Peptides

Biotech Peptides (biotechpeptides.com), operating from San Diego, California for approximately five years, offers one of the largest catalogs in the industry with 87+ peptides including rare compounds like IGF-1 DES and B7-33 that few vendors stock. Their Trustpilot rating of 4.8 out of 5 from over 301 reviews reflects strong customer satisfaction, and they are notable for offering a money-back guarantee — virtually unheard of in the peptide industry. Pricing is competitive, with BPC-157 (5mg) around $43–50 and bulk discounts available. The company accepts credit cards and PayPal and ships same-day for orders placed before noon. However, third-party testing transparency is a weakness — one MuscleChemistry review noted the absence of publicly accessible independent testing data, and PeptideDeck’s 2026 ranking flagged “quality inconsistent across the catalog and COA availability varies by product.”

3. Verified Peptides

Verified Peptides (verifiedpeptides.com) holds the distinction of being the highest-rated peptide supplier in this research, with a perfect 5.0 out of 5 Trustpilot score from 297 reviews. The company pioneered third-party testing in the peptide space, publishing over 300 lab reports from Janoshik — a well-respected independent laboratory recognized across the research chemical community. Testing covers HPLC purity, active weight/net peptide content, endotoxins, sterility, and TFA content. As of November 2025, the company added endotoxin testing that few competitors offer at its price point. Products ship with ice box packaging for temperature control, and the company offers a price-match guarantee. One Trustpilot reviewer captured the appeal: “I’ve tried several peptide companies but this one has been the best, most reliable and has the highest quality peptides. I look up their 3rd party testing and it is also legitimate.”

Conclusion: The Grey Market’s Twilight and What Comes Next

Peptide Sciences’ closure represents something larger than a single business shutting down. It marks the beginning of the end for the “research use only” business model that sustained the grey-market peptide ecosystem for over a decade. The convergence of FDA enforcement, DOJ criminal prosecutions, ITC exclusion orders, state attorney general actions, Big Pharma litigation, and payment processor restrictions has created an environment where operating a research peptide vendor carries existential legal and financial risk. The company’s use of “voluntarily” in its closure statement — combined with its 2023 FDA warning letter and the Amino Asylum raid as cautionary precedent — strongly suggests Peptide Sciences chose to close before facing seizure, criminal charges, or worse.

For the community, the path forward is bifurcating. Researchers who want to continue sourcing peptides from grey-market vendors face a shrinking, riskier landscape where quality control and vendor longevity are increasingly uncertain. The RFK Jr. reversal, if formalized, could redirect demand toward regulated compounding pharmacies — a legitimate channel, but one with higher costs and prescription requirements. Meanwhile, the global pharmaceutical peptide market continues to boom, valued at roughly $39 billion and growing rapidly. The peptide industry is not dying. It is transforming. And Peptide Sciences, for all its years of dominance, was unable to survive the transformation.